2021 | Synthekine

Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System

December 23, 2021/in 2021, news/by Emily Hennes

December 23, 2021

Synthekine Establishes Collaboration with Merck to Develop Therapeutic Candidates Using its Proprietary Surrogate Cytokine Agonist Platform

November 16, 2021/in 2021, news/by Emily Hennes

November 1, 2021

Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors

November 16, 2021/in 2021, news/by Emily Hennes

October 28, 2021

Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform

November 16, 2021/in 2021, news/by Emily Hennes

June 10, 2021

Synthekine Expands Board of Directors, Management Team and Scientific Advisory Board with New Key Appointments

November 16, 2021/in 2021, news/by Emily Hennes

June 3, 2021

Synthekine Appoints Internationally Recognized Cancer Immunotherapy Leader Naiyer Rizvi, M.D., as Chief Medical Officer

November 16, 2021/in 2021, news/by Emily Hennes

May 3, 2021

Synthekine Licenses Additional Cytokine Programs

November 16, 2021/in 2021, news/by Emily Hennes

April 22, 2021

Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities

November 16, 2021/in 2021, news/by Emily Hennes

April 10, 2021

Synthekine Strengthens Leadership with Board of Directors Expansion and Scientific Advisory Board Formation

November 16, 2021/in 2021, news/by Emily Hennes

February 4, 2021